The placebo-controlled study is aimed at assessing the safety and efficacy of zodasiran in adults and adolescents with HoFH.

Arrowhead Pharmaceuticals recently received a rating upgrade from SVB Financial and a price target that implies a 44% gain up ahead. Arrowhead Pharmaceuticals is a precommercial-stage drugmaker ...

PASADENA, Calif.-- (BUSINESS WIRE)-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced a global licensing and collaboration agreement with Sarepta Therapeutics (NASDAQ: SRPT). Upon ...

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced presentation of preclinical data supporting the advancement of two first-in-class clini ...

We recently published a list of the 12 Most Oversold Healthcare Stocks to Buy Now. In this article, we are going to take a look at where Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) stands ...

Arrowhead Pharmaceuticals, Inc. today announced that it is scheduled to participate in the following upcoming investor events:. BofA Securities 2025 Health Care Conference– May 13-15, 2025 ...

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Q4 2024 Earnings Call Transcript November 26, 2024 Arrowhead Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $-1.38 EPS ...

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has dosed the first subject in the YOSEMITE Phase 3 clinical trial of zodasiran, the company’s investigational RNA ...

Arrowhead Pharmaceuticals has a promising pipeline of drug candidates based on RNAi methodology. Read why investors may want to look at ARWR stock.

The firm is hoping to show that the RNAi drug can treat HoFH by reducing production of ANGPTL3, which regulates lipid and lipoprotein metabolism.

PASADENA, Calif., May 07, 2025--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming investor events: ...